NCT07244471Completed
Water-injecting Endoscopic Submucosal Dissection for Early Gastric Cancer: a Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 24 Nov 2025
Brief summary (registry, in English)
Endoscopic submucosal dissection (ESD) is a technically difficult and time-consuming procedure. Several water-jet knives have been developed to address this issue. The aim of this study was to develop a new ESD method using continuous low-pressure water injection at 1-2 atmosphere with a tip-injected electric knife while dissection simultaneous cutting, dissection, electrocoagulation, and hemostasis, which was so called as water-injecting ESD (W-ESD) to treat early gastric cancer and compare the efficacy and safety with conventional methods.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 548 (actual)
- First submitted
- 17 Nov 2025
- Start date
- Jan 2019
- Primary completion date
- Dec 2024
- Lead sponsor
- Shanghai East Hospital
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07244471
What you commit to
- Study type: Observational
- Participants enrolled: 548
- From Jan 2019 to the primary completion date, Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- difficulty obtaining consent due to psychiatric disorder;
- history of gastrectomy or gastrointestinal reconstruction surgery.
Other
- pregnancy or breastfeeding;
- multiple lesions;
Who the study is looking for
- age ≥ 18 years;
- histologically proven early gastric adenocarcinoma;
- meeting the absolute or expanded indication for ESD according to the Japanese gastric cancer treatment guidelines 2021 ;
- Eastern Cooperative Oncology Group performance status ≤ 2;
- adequate hematological function (hemoglobin ≥ 9 g/dL, platelets ≥ 50 000/mm3，international normalized ratio\<1.5);
- sufficient renal function (serum creatinine ≤ 2.0 mg/dL); and (7) adequate hepatic function (serum aspartate aminotransferase ≤ 100 IU/L, serum alanine aminotransferase ≤ 100 IU/L).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai East Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.